Parikshit Somani's Four-Year Suspension: Trimetazidine, the Burden of Proof, and the Monitoring Gap at Tennis's Base Tier

Three phrases from the written decision — “scientifically implausible,” “highly speculative,” “unconvincing” — do not read like the language of a sample report. They read like a verdict on who carries the burden of proof. On Wednesday the ITIA, the International Tennis Integrity Agency, confirmed that trimetazidine was found in Parikshit Somani's sample, and that the consequence is a four-year suspension running to September 2029.

Most of the coverage will lean on the “four years.” The number that does more work is 256 — his career-high doubles ranking — alongside his age, 26. Put those two together and you get a fair reading of what the sanction actually costs, and of which floor of tennis's monitoring architecture this case has opened up.

Context: from a Rusholme bedroom to a sample in Astana

In July 2026, in a bedroom in Rusholme, I charted the Wimbledon final in pencil. Twenty-nine games went onto paper: Cilic won 18 of 44 points on second serve, Federer converted three of seven break points. The rule from that afternoon has not moved — the opening paragraph carries at least one hand-counted number, because numbers travel further than adjectives.

Somani's case begins at a lower-tier event in Astana, Kazakhstan, last year. The sample taken there returned trimetazidine, an S4-class metabolic modulator and anti-anginal heart medication that is prohibited at all times under the World Anti-Doping Agency list, in and out of competition alike.

The defence was specific: food contamination, through a family member's preparation or handling. A hearing took place in August. The tribunal rejected the explanation, finding the source of contamination unproven and the hypothesis scientifically unsustainable.

And then there is 256. It is the highest doubles ranking of his career, and no singles ranking appears anywhere in the report. A career best in doubles points to a doubles-leaning profile, sitting well below the main-tour cut. That base tier of tennis rarely has a physio, a nutritionist or a data team — and it is precisely the tier this case belongs to.

The burden of proof: three steps, one door

The whole weight of an anti-doping case rests on a single question: how did the prohibited substance enter the body, and who has to prove it?

An athlete must establish three separate things at once: that the explanation of the source is credible, that it survives scientific scrutiny, and then, separately, that there was no fault or negligence. A crack in any one of those steps puts the sanction back at the four-year mark.

On step one, Somani argued food contamination. On step two, the tribunal demolished the structure. Step three never arises, because without a proven source there is no foundation for a no-fault claim. It matters that he argued only the family-food route, without leaving a therapeutic-use exemption or a contaminated-supplement route open; that narrows the appeal surface further.

Trimetazidine is not a random detail. It is one of the few substances against which food-contamination arguments are raised most often — and succeed least often in recent years.

The reason is not hard to follow. For the argument to work, the athlete has to show whose food it was, how it was contaminated, what dose was involved, and why the body returned precisely that quantity. Once those four answers are cross-checked across separate sources, the story that emerges is either clean or impossible. There is no middle ground.

One comparison is worth keeping straight, because it sits directly beside this ruling: Kamila Valieva. Same substance, same four-year outcome. Tribunals have been hardening their tone across trimetazidine cases, and this decision reinforces that line. A second, older reference — Sun Yang's 2026 trimetazidine matter — is cited here only for the substance; the procedural history is different, and merging the two would be a mistake.

The hearing was in August; the announcement came on a Wednesday. That gap matches ordinary arbitration turnaround. The suspension ends in September 2029 — a fixed date, not an open-ended ban. What the announcement does not make clear is the calculation anchor: provisional suspension or sample collection. That small gap grows large when documents are reconciled, because it is the basis on which every case's end date is computed.

Beyond the burden of proof sits the scope of the sanction. It does not merely stop match play. It bars competing, coaching, and even attendance at ITF, ATP, WTA, Grand Slam and national-federation events. Under the WADA code that breadth is standard, and it is the heaviest part of the penalty: four years away from courts removes any alternative ladder back into the profession.

Then there is the ranking question. Tennis offers protected ranking for long injury layoffs; doping bans generally do not qualify. So the return would begin from zero, from qualifying rounds — a career stalled at 26 re-entering at 30, with a completely new points ledger.

The economics deserve a line too. A doubles ranking of 256 places a player at the level where travel, accommodation and entry fees often leave him at break-even. There is no guaranteed club income to fall back on anywhere. Four years of ineligibility does not only consume playing years; it rewrites the arithmetic of an actual life.

The contrarian reading: what the headline says, and what it buries

The easy reading is that a career was destroyed, that a 26-year-old returns at 30, that tennis lost a prospect. True, and incomplete. The real question is what he actually lost.

A doubles peak of 256, with no singles ranking cited, means he was already outside main-tour competition. What the ban took from him was a fight to survive at tennis's base. The four-year headline suggests something enormous was seized; competitively the loss is small — professionally it is close to final. Two different ledgers, and they should be stated separately.

Second, the Valieva comparison. The similarity it shows is one of defence strategy, not of facts. The news instinct is to anchor an obscure case to a famous precedent so readers catch on quickly. The practical value is not there but here: the tribunal posture toward trimetazidine food-contamination defences is tightening, and that is a story about a system, not a player.

That is why the most instructive part of this case is not Somani himself. Had he been a main-tour star, with a team, a nutritionist and a supplement log, the chain of evidence would have looked different — a file, an invoice, a photograph of a medicine box. For a player competing alone, with no physio and no nutritionist, the only evidence available is the family kitchen. Six days at the National Tennis Complex taught me that silence has a serve-and-volley rhythm — but this is not that silence. This is the silence of rejection, the kind that says nobody stood beside the player.

One conclusion follows. Testing density at the base tier is lower, so sampling imbalances are normal. The larger gap sits earlier in the process — schools without courts, schools without coaches, and no support structure teaching junior players to keep track of medication, food and nutrition from the beginning. Academies launched under famous names work on the signboard; the habit is not built there.

Looking ahead: what to track

Three things. First, the appeal question: the final door in tennis doping cases is the Court of Arbitration for Sport. An argument that failed in August is unlikely to flip suddenly without new evidence, but the window does not close. Second, the ITIA's published sanctions list, which will confirm the start date and make the September 2029 figure auditable for future trimetazidine cases. Third, the shape of testing itself. When the tour stopped in 2026, I rebuilt Bangladesh's Davis Cup record out of thirty-four years of archive dust — 41 ties, 178 rubbers. The lesson was that empty stands, cancelled calendars and closed courts must be written as precisely as winning points. What has to be written today is not a player's name but a benchmark, against which the next trimetazidine dispute will be measured.

The question is simple enough: when the next case of this kind arrives, will the tribunal use the same language, or somewhere soften? The answer is probably already written into Wednesday's ruling.